Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis

Jin Li,1 Yajun Li,2 Ruolan Zeng,2 Jingguan Lin,1 Meizuo Zhong,3 Xianling Liu,4 Yizi He,2 Junqiao He,2 Zhou Ouyang,2 Lijun Huang,2 Ling Xiao,5 Hui Zhou2 1Department of Comprehensive Chemotherapy/Daytime Chemotherapy, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 2Depar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li J, Li Y, Zeng R, Lin J, Zhong M, Liu X, He Y, He J, Ouyang Z, Huang L, Xiao L, Zhou H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	extranodal natural killer/t-cell lymphoma nasal type chemotherapy courses low-risk Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e79343406de54cd189c8adbab754990b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e79343406de54cd189c8adbab754990b
record_format	dspace
spelling	oai:doaj.org-article:e79343406de54cd189c8adbab754990b2021-12-02T11:52:51ZOptimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis1178-203Xhttps://doaj.org/article/e79343406de54cd189c8adbab754990b2020-12-01T00:00:00Zhttps://www.dovepress.com/optimal-courses-of-chemotherapy-combined-with-radiotherapy-for-low-ris-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XJin Li,1 Yajun Li,2 Ruolan Zeng,2 Jingguan Lin,1 Meizuo Zhong,3 Xianling Liu,4 Yizi He,2 Junqiao He,2 Zhou Ouyang,2 Lijun Huang,2 Ling Xiao,5 Hui Zhou2 1Department of Comprehensive Chemotherapy/Daytime Chemotherapy, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 2Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 3Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 4Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 5Department of Histology and Embryology, School of Basic Medical Science, Central South University, Changsha, Hunan, People’s Republic of ChinaCorrespondence: Hui ZhouDepartment of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of ChinaTel +86 731 89762281Email zhouhui9403@126.comPurpose: This retrospective study compared effectiveness between ≤ 4 cycles and ≥ 5 cycles of L-asparaginase/pegaspargase-based chemoradiation in newly diagnosed low-risk extranodal natural killer/T-cell lymphoma (ENKTL), nasal type classified according to the Prognostic Index of Natural Killer (PINK) lymphoma model.Patients and Methods: Patients were categorized into ≤ 4-cycle (2– 4 chemotherapy cycles, n = 166) and ≥ 5-cycle groups (5– 6 cycles, n = 86). Propensity score matching analysis was used to reduce potential confounding bias between the two groups. Treatment responses, adverse events, and survival outcomes between the two groups were analyzed.Results: No matter before or after matching (65 in the ≤ 4-cycle group, 65 in the ≥ 5-cycle group), response rates and survival outcomes were similar between the ≤ 4-cycle and ≥ 5-cycle groups. Incidences of grade 1– 2 anemia and transaminase elevation were higher in the ≥ 5-cycle group. After matching, for stage IE disease, there were no differences in response rates and survival outcomes between the two groups. For stage IIE disease, the complete response rate was higher in the ≥ 5-cycle group (72.4% vs 92.6%, p = 0.049), and the 3-year overall survival (65.5% vs 85.2%, p = 0.024) and 3-year progression-free survival (58.6% vs 81.5%, p = 0.027) rates were significantly extended in the ≥ 5-cycle group.Conclusion: When chemoradiotherapy strategies with L-asparaginase/pegaspargase-based regimens are applied to modern low-risk ENKTL patients classified according to the PINK model, it may be better to moderately extend chemotherapy courses in patients with stage IIE disease.Keywords: extranodal natural killer/T-cell lymphoma, nasal type, chemotherapy courses, low-riskLi JLi YZeng RLin JZhong MLiu XHe YHe JOuyang ZHuang LXiao LZhou HDove Medical Pressarticleextranodal natural killer/t-cell lymphomanasal typechemotherapy courseslow-riskTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 1151-1163 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	extranodal natural killer/t-cell lymphoma nasal type chemotherapy courses low-risk Therapeutics. Pharmacology RM1-950
spellingShingle	extranodal natural killer/t-cell lymphoma nasal type chemotherapy courses low-risk Therapeutics. Pharmacology RM1-950 Li J Li Y Zeng R Lin J Zhong M Liu X He Y He J Ouyang Z Huang L Xiao L Zhou H Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis
description	Jin Li,1 Yajun Li,2 Ruolan Zeng,2 Jingguan Lin,1 Meizuo Zhong,3 Xianling Liu,4 Yizi He,2 Junqiao He,2 Zhou Ouyang,2 Lijun Huang,2 Ling Xiao,5 Hui Zhou2 1Department of Comprehensive Chemotherapy/Daytime Chemotherapy, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 2Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 3Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 4Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 5Department of Histology and Embryology, School of Basic Medical Science, Central South University, Changsha, Hunan, People’s Republic of ChinaCorrespondence: Hui ZhouDepartment of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of ChinaTel +86 731 89762281Email zhouhui9403@126.comPurpose: This retrospective study compared effectiveness between ≤ 4 cycles and ≥ 5 cycles of L-asparaginase/pegaspargase-based chemoradiation in newly diagnosed low-risk extranodal natural killer/T-cell lymphoma (ENKTL), nasal type classified according to the Prognostic Index of Natural Killer (PINK) lymphoma model.Patients and Methods: Patients were categorized into ≤ 4-cycle (2– 4 chemotherapy cycles, n = 166) and ≥ 5-cycle groups (5– 6 cycles, n = 86). Propensity score matching analysis was used to reduce potential confounding bias between the two groups. Treatment responses, adverse events, and survival outcomes between the two groups were analyzed.Results: No matter before or after matching (65 in the ≤ 4-cycle group, 65 in the ≥ 5-cycle group), response rates and survival outcomes were similar between the ≤ 4-cycle and ≥ 5-cycle groups. Incidences of grade 1– 2 anemia and transaminase elevation were higher in the ≥ 5-cycle group. After matching, for stage IE disease, there were no differences in response rates and survival outcomes between the two groups. For stage IIE disease, the complete response rate was higher in the ≥ 5-cycle group (72.4% vs 92.6%, p = 0.049), and the 3-year overall survival (65.5% vs 85.2%, p = 0.024) and 3-year progression-free survival (58.6% vs 81.5%, p = 0.027) rates were significantly extended in the ≥ 5-cycle group.Conclusion: When chemoradiotherapy strategies with L-asparaginase/pegaspargase-based regimens are applied to modern low-risk ENKTL patients classified according to the PINK model, it may be better to moderately extend chemotherapy courses in patients with stage IIE disease.Keywords: extranodal natural killer/T-cell lymphoma, nasal type, chemotherapy courses, low-risk
format	article
author	Li J Li Y Zeng R Lin J Zhong M Liu X He Y He J Ouyang Z Huang L Xiao L Zhou H
author_facet	Li J Li Y Zeng R Lin J Zhong M Liu X He Y He J Ouyang Z Huang L Xiao L Zhou H
author_sort	Li J
title	Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis
title_short	Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis
title_full	Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis
title_fullStr	Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis
title_full_unstemmed	Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis
title_sort	optimal courses of chemotherapy combined with radiotherapy for low-risk extranodal natural killer/t-cell lymphoma, nasal type: a propensity score matching analysis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/e79343406de54cd189c8adbab754990b
work_keys_str_mv	AT lij optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT liy optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT zengr optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT linj optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT zhongm optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT liux optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT hey optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT hej optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT ouyangz optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT huangl optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT xiaol optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis AT zhouh optimalcoursesofchemotherapycombinedwithradiotherapyforlowriskextranodalnaturalkillertcelllymphomanasaltypeapropensityscorematchinganalysis
_version_	1718394959202091008

Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis

Ejemplares similares